ADVFN Logo
Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.
AlloVir Inc

AlloVir Inc (ALVR)

0.499
-0.031
(-5.85%)
At close: December 05 4:00PM
0.499
0.00
( 0.00% )
After Hours: 5:01PM

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Key stats and details

Current Price
0.499
Bid
0.4802
Ask
0.5218
Volume
591,373
0.4983 Day's Range 0.55
0.4758 52 Week Range 2.485
Market Cap
Previous Close
0.53
Open
0.55
Last Trade
1
@
0.5098
Last Trade Time
16:57:19
Financial Volume
$ 306,389
VWAP
0.518097
Average Volume (3m)
333,766
Shares Outstanding
115,536,550
Dividend Yield
-
PE Ratio
-0.31
Earnings Per Share (EPS)
-1.65
Revenue
-
Net Profit
-190.42M

About AlloVir Inc

AlloVir Inc is a late clinical-stage cell therapy company. It is developing allogeneic T cell therapies to treat and prevent devastating viral diseases. The firm's pipeline includes ALVR106, ALVR109, ALVR108, and others. The company's product candidate, Viralym-M, is a multi-VST therapy targeting fi... AlloVir Inc is a late clinical-stage cell therapy company. It is developing allogeneic T cell therapies to treat and prevent devastating viral diseases. The firm's pipeline includes ALVR106, ALVR109, ALVR108, and others. The company's product candidate, Viralym-M, is a multi-VST therapy targeting five viruses namely BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, and human herpesvirus 6. Show more

Sector
Biological Pds,ex Diagnstics
Industry
Biological Pds,ex Diagnstics
Website
Headquarters
Wilmington, Delaware, USA
Founded
-
AlloVir Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker ALVR. The last closing price for AlloVir was $0.53. Over the last year, AlloVir shares have traded in a share price range of $ 0.4758 to $ 2.485.

AlloVir currently has 115,536,550 shares outstanding. The market capitalization of AlloVir is $61.23 million. AlloVir has a price to earnings ratio (PE ratio) of -0.31.

ALVR Latest News

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.041-7.592592592590.540.560.47583285930.52279676CS
4-0.531-51.55339805831.031.030.47585089550.60135662CS
12-0.2511-33.47553659510.75011.050.47583337660.72777671CS
26-0.2621-34.43699908030.76111.050.47582758720.73982029CS
52-1.561-75.77669902912.062.4850.47587708440.81359758CS
156-17.141-97.171201814117.6420.680.47586881243.53340809CS
260-22.321-97.813321647722.8248.960.47585623537.40591437CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
ZBAOZhibao Technology Inc
$ 6.2942
(146.83%)
1.68M
RADXRadiopharm Theranostics Ltd
$ 22.88
(29.49%)
10.42k
PWMPrestige Wealth Inc
$ 1.38
(25.45%)
149.38k
PGHLPrimega Group Holdings Ltd
$ 1.60
(19.85%)
2.28M
AOUTAmerican Outdoor Brands Inc
$ 12.77
(17.16%)
40.97k
ORISOriental Rise Holdings Ltd
$ 9.98
(-82.18%)
2.96M
BOCNUBlue Ocean Acquisition Corporation
$ 9.23
(-18.03%)
100
FOXXFoxx Development Holdings Inc
$ 4.10
(-17.17%)
28.67k
ZCMDZhongchao Inc
$ 1.20
(-16.08%)
4.26k
BOCNBlue Ocean Acquisition Corporation
$ 9.00
(-16.01%)
465
CDIOCardio Diagnostics Holdings Inc
$ 0.5391
(16.09%)
9.12M
SVMHSRIVARU Holding Ltd
$ 0.0347
(-0.86%)
7.4M
SMCISuper Micro Computer Inc
$ 41.31
(0.41%)
6.85M
ORISOriental Rise Holdings Ltd
$ 9.98
(-82.18%)
2.96M
SOUNSoundHound AI Inc
$ 13.69
(2.70%)
2.63M

ALVR Discussion

View Posts
learningcurve2020 learningcurve2020 2 months ago
Then everything went dark as the cash dwindles.

>>Company to discontinue its three Phase 3 posoleucel studies following separate, pre-planned DSMB futility analyses concluding the studies were unlikely to meet their primary endpoints; no safety concerns identified

Company to prioritize capital preservation and review strategic options

AlloVir reported $213.3 million in cash, cash equivalents, and short-term investments as of September 30, 2023
๐Ÿ‘๏ธ0
Monksdream Monksdream 6 months ago
ALVR under $2
๐Ÿ‘๏ธ0
Monksdream Monksdream 9 months ago
ALVR 1O Q 2/26
๐Ÿ‘๏ธ0
microcapbiotech microcapbiotech 11 months ago
AlloVir shedding 95% of its staff after discontinuing T cell therapy trial
https://www.morningstar.com/news/marketwatch/202401041038/allovir-shedding-95-of-its-staff-after-discontinuing-t-cell-therapy-trial
๐Ÿ‘๏ธ0
starkd748 starkd748 11 months ago

26s
๐Ÿ‘๏ธ0
Monksdream Monksdream 11 months ago
ALVR new 52 week low
๐Ÿ‘๏ธ0
starkd748 starkd748 11 months ago
Waiting to see if .20s come
๐Ÿ‘๏ธ0
KOmani KOmani 11 months ago
Gilead owns about 13 Million shares of the total 114 Million outstanding.

I think if they offered $1.50 they could buy the rest of the shares for basically the cash on hand less liabilities.

Is the value of the pipeline $0?

I doubt it, but worse case it is.

I don't know, but $0.75-0.80 seems decent even for a bounce just to $1

I am more saying why I would get in should there start to be buy in and support from bigger pockets.
๐Ÿ‘๏ธ0
redspinelpinktopaz redspinelpinktopaz 11 months ago
Agree. Not too bright addition.
๐Ÿ‘๏ธ0
Monksdream Monksdream 11 months ago
ALVR new 52 week low
๐Ÿ‘๏ธ0
Lwrnc2052 Lwrnc2052 11 months ago
Tpet
๐Ÿ‘๏ธ0
jobynimble jobynimble 11 months ago
Exhibit 99.1 Press release: https://www.sec.gov/Archives/edgar/data/1754068/000119312523301777/d671953dex991.htm

AlloVir Provides Updates on Phase 3 Clinical Development Program for Posoleucel, an Allogeneic Virus-Specific T Cell Therapy
Company to discontinue its three Phase 3 posoleucel studies following separate, pre-planned DSMB futility analyses concluding the studies were unlikely to meet their primary endpoints; no safety concerns identified
Company to prioritize capital preservation and review strategic options

AlloVir reported $213.3 million in cash, cash equivalents, and short-term investments as of September 30, 2023
Waltham, Mass โ€“ December 22, 2023 โ€“ AlloVir, Inc. (Nasdaq: ALVR), an allogeneic T cell immunotherapy company, today provided an update on its three Phase 3 clinical trials with posoleucel, an investigational off-the-shelf multi-virus-specific T cell therapy, which targets six viral pathogens in immunocompromised individuals: adenovirus (AdV), BK virus (BKV), cytomegalovirus (CMV), Epstein-Barr virus (EBV), human herpesvirus-6 (HHV-6) and JC virus (JCV). The company will discontinue its three global Phase 3 posoleucel studies โ€“ for prevention of clinically significant infections or diseases by multiple viruses, treatment of virus-associated hemorrhagic cystitis (vHC), and treatment of adenovirus (AdV) โ€“ following allogeneic hematopoietic cell transplant (allo-HCT). The company made the determination following three pre-planned analyses by three independent Data Safety Monitoring Boards (DSMBs) each of which recommended stopping its respective trial for futility after a review of the data suggested that each study was unlikely to meet its primary endpoint. There were no observed safety concerns raised by any of the DSMBs.

AlloVir is in the process of notifying regulatory agencies and clinical trial investigators involved in these trials of the findings.
โ€œWhile we are disappointed by the unexpected outcome of these trials, we are encouraged by the apparent safety profile of posoleucel,โ€ said Diana Brainard, MD, Chief Executive Officer of AlloVir. โ€œIn light of the DSMB recommendations, we will discontinue the prevention, vHC and AdV Phase 3 trials. We will continue to analyze the data from these studies to understand any variables that may have impacted outcomes or any apparent subpopulation benefits. We thank the patients, investigators and staff who participated in the trials.โ€

Dr. Brainard continued, โ€œWe established pre-planned futility analyses across these three Phase 3 trials, as each assessed a potentially highly innovative treatment for patients suffering with severe and complex medical conditions lacking significant prior clinical development, and we also expected the trials would require substantial additional capital to bring them to completion. With these current results, we will immediately shift our focus to preserve our substantial remaining capital, review our pipeline, and assess strategic options.โ€

AlloVir will review strategic alternatives for the Company and its portfolio of virus-specific T cell therapies. Such alternatives may include a merger, sale, divestiture of assets, licensing, or other strategic transaction. As of September 30, 2023, AlloVir had cash, cash equivalents and short-term investments of $213.3 million.

About AlloVirโ€™s Earlier Stage Virus-Specific T cell Pipeline

Adult Kidney Transplantation

AlloVir has earlier reported the results of its completed Phase 2 randomized, placebo-controlled trial evaluating posoleucel for the treatment of BKV infection in adult kidney transplant patients. After 24 weeks of treatment, 39% of patients receiving posoleucel experienced a =1-log viral load reduction, compared to 14% of patients receiving placebo.

Acute Respiratory Infection

The company has completed Part A of a randomized, placebo-controlled Phase 1b/2a trial with ALVR106 in 14 stem cell or solid organ transplant patients. ALVR106 is an investigational allogeneic, off-the-shelf, multi-virus-specific VST therapy candidate designed to target diseases caused by human metapneumovirus (hMPV), influenza, parainfluenza virus (PIV) and respiratory syncytial virus (RSV). Data has been accepted for presentation at a scientific conference in the first quarter of 2024.
Chronic Hepatitis B Infection

ALVR107 is an investigational allogeneic, off-the-shelf VST therapy designed to target hepatitis B virus (HBV)-infected cells and potentially cure patients with chronic HBV infection. Preclinical and IND-enabling studies support the advancement of ALVR107 into a clinical proof of concept study as a next step.

About AlloVir

AlloVir is an allogeneic T cell immunotherapy company with a focus on restoring natural immunity against life-threatening viral diseases in pediatric and adult patients with weakened immune systems. The companyโ€™s innovative and proprietary technology platforms leverage off-the-shelf, allogeneic, single- and multi-virus-specific T cells for patients with T cell deficiencies who are at risk from the life-threatening consequences of viral diseases. AlloVirโ€™s technology and manufacturing process enable the potential for the treatment and prevention of a spectrum of devastating viruses with each single allogeneic cell therapy. For more information, visit www.allovir.com or follow us on X or LinkedIn.
๐Ÿ‘๏ธ0
jobynimble jobynimble 11 months ago
8-K filing:https://www.sec.gov/ix?doc=/Archives/edgar/data/1754068/000119312523301777/d671953d8k.htm

Item 7.01
Regulation FD Disclosure
On December 22, 2023, AlloVir, Inc. (โ€œAlloVirโ€) issued a press release titled โ€œAlloVir Provides Updates on Phase 3 Clinical Development Program for Posoleucel, an Allogeneic Virus-Specific T-Cell Therapy.โ€ The press release is attached hereto as Exhibit 99.1 and is incorporated into this Item 7.01 by reference.
The information in Item 7.01 of this Current Report on Form 8-K and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed โ€œfiledโ€ for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the โ€œExchange Actโ€) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 8.01
Other Events.
On December 22, 2023, AlloVir announced that it is discontinuing enrollment in its three ongoing Phase 3 Posoleucel studies for (i) prevention of clinically significant infections or diseases by multiple viruses, (ii) treatment of virus-associated hemorrhagic cystitis, and (iii) treatment of adenovirus, all following allogeneic hematopoietic cell transplant.

Item 9.01.
Financial Statements and Exhibits.
(d) Exhibits

Exhibit No. Description
99.1 Press release dated December 22, 2023
104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
๐Ÿ‘๏ธ0
microcapbiotech microcapbiotech 11 months ago
They did say: "we are encouraged by the apparent safety profile of posoleucel".
Yes, water also has a great safety profile, but doesn't cure a damn thing except thirst.
NOT GOOD - NOT GOOD AT ALL.
👍️ 1
microcapbiotech microcapbiotech 11 months ago
NOT GOOD NEWS.
๐Ÿ‘๏ธ0
starkd748 starkd748 11 months ago
The chart never lies
๐Ÿ‘๏ธ0
Handbag Handbag 11 months ago
Damn, That was quick
๐Ÿ‘๏ธ0
starkd748 starkd748 11 months ago
I'm going to wait till next week
๐Ÿ‘๏ธ0
starkd748 starkd748 11 months ago
Wow I love the technicals analysis....I didn't read the PR or anything I just knew the chart was fugly ugly lol... Fundamentals don't mean squat ....I need to check to see if this is oversold look up the Fibonacci retracement and the stochastic rsi...
๐Ÿ‘๏ธ0
KOmani KOmani 11 months ago
Below $1 now.

Report said they have $213.3 million as of Sept 30

With 114 million shares outstanding, this seems cheap?

If this catches a bid, might see a bit of a pop.
๐Ÿ‘๏ธ0
starkd748 starkd748 1 year ago
Need this below 1.00 then I buy for a flip
๐Ÿ‘๏ธ0
jobynimble jobynimble 1 year ago
AlloVir to Present at the Piper Sandler 35th Annual Healthcare Conference
November 16 2023 - 07:00AM
Business Wire
AlloVir, Inc. (Nasdaq: ALVR), a late-clinical stage allogeneic T cell immunotherapy company, today announced that Diana Brainard, M.D., Chief Executive Officer, will participate in a fireside chat at the Piper Sandler 35th Annual Healthcare Conference in New York City, NY on Tuesday, November 28, 2023 at 10:00 a.m. ET.

A live webcast and archived replay of the presentation will be available on the Investors & Press section of the AlloVir website at https://ir.allovir.com.

About AlloVir

AlloVir is a leading late-clinical stage cell therapy company focused on restoring natural immunity against life-threatening viral diseases in pediatric and adult patients with weakened immune systems. The company's innovative and proprietary technology platform leverages off-the-shelf, allogeneic, single- and multi-virus-specific T cells for patients with T cell deficiencies who are at risk from the life-threatening consequences of viral diseases. AlloVir's technology and manufacturing process enable the potential for the treatment and prevention of a spectrum of devastating viruses with each single allogeneic cell therapy. The company is advancing multiple mid- and late-stage clinical trials across its product portfolio. For more information, visit www.allovir.com or follow us on Twitter/X or LinkedIn.


View source version on businesswire.com: https://www.businesswire.com/news/home/20231116711808/en/
๐Ÿ‘๏ธ0
starkd748 starkd748 1 year ago
I'm out come below 1s
💀 1 ☠️ 1 ⚰️ 1
starkd748 starkd748 1 year ago
No below 1s but my 1.30s look good
๐Ÿ‘๏ธ0
starkd748 starkd748 1 year ago
Tank below 1s
๐Ÿ‘๏ธ0
starkd748 starkd748 1 year ago
Her come 1.20s
๐Ÿ‘๏ธ0
starkd748 starkd748 1 year ago
The chart is still in free fall looking for a bottom
๐Ÿ‘๏ธ0
Handbag Handbag 1 year ago
No way. Will be a 25-30 Million market cap soon.
๐Ÿ‘๏ธ0
starkd748 starkd748 1 year ago
Will 1.20s hold
๐Ÿ‘๏ธ0
starkd748 starkd748 1 year ago
Yes tank more
๐Ÿ‘๏ธ0
starkd748 starkd748 1 year ago
Come on below 1s please
👧 1
starkd748 starkd748 1 year ago
Need more read below 1s would be a possible buy
🤥 1
starkd748 starkd748 1 year ago
Need more
๐Ÿ‘๏ธ0
starkd748 starkd748 1 year ago
Need more tankage
๐Ÿ‘๏ธ0
starkd748 starkd748 1 year ago
Tank baby tank below 1s
👧 1
starkd748 starkd748 1 year ago
More red this week nearing a bottom easy flip once stochastic hit 0.... below 1.00 would be excellent
👧 1 🤥 1
starkd748 starkd748 1 year ago
Almost ready
👧 1
starkd748 starkd748 1 year ago
Tank hard then I buy for a flip
👧 1
microcapbiotech microcapbiotech 1 year ago
Bought more today @ $2.16
๐Ÿ‘๏ธ0
microcapbiotech microcapbiotech 1 year ago
Bought more today again under $3
๐Ÿ‘๏ธ0
Klinsmann Klinsmann 1 year ago
still on watch
๐Ÿ‘๏ธ0
microcapbiotech microcapbiotech 1 year ago
Bought more today under $3.
๐Ÿ‘๏ธ0
microcapbiotech microcapbiotech 1 year ago
I bought in at under $3. On 6-29 10% owner Gilead Sciences Inc acquired a total 2,930,870 shares an average price of $3.75.
๐Ÿ‘๏ธ0
microcapbiotech microcapbiotech 1 year ago
Just started a position in ALVR.
๐Ÿ‘๏ธ0
learningcurve2020 learningcurve2020 2 years ago
Nobody? What about PL is he here?
๐Ÿ‘๏ธ0

Your Recent History

Delayed Upgrade Clock